{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:05:41Z","timestamp":1783987541994,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-026-04905-7","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:06:23Z","timestamp":1779275183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcome and factors affecting prognosis in treat and extend treatment for neovascular age-related macular degeneration-a real world study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7088-7303","authenticated-orcid":false,"given":"Fatma Sema","family":"Akkan Aydogmus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugba","family":"Gursoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozdemir","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozgul Ucar","family":"Elalmis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Defne","family":"Kalayci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"issue":"5","key":"4905_CR1","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1136\/bjophthalmol-2017-311258","volume":"102","author":"RRA Bourne","year":"2018","unstructured":"Bourne RRA, Jonas JB, Bron AM, Cicinelli MV, Das A, Flaxman SR, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: magnitude, temporal trends and projections. Br J Ophthalmol. 2018;102(5):575\u201385. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311258.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"4905_CR2","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/aos.13565","volume":"96","author":"M Ashraf","year":"2018","unstructured":"Ashraf M, Souka A, Adelman RA. Age-related macular degeneration: using morphological predictors to modify current treatment protocols. Acta Ophthalmologica. 2018;96(2):120\u201333. https:\/\/doi.org\/10.1111\/aos.13565.","journal-title":"Acta Ophthalmologica"},{"issue":"1","key":"4905_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.survophthal.2013.03.009","volume":"59","author":"RP Finger","year":"2014","unstructured":"Finger RP, Wickremasinghe SS, Baird PN, Guymer RH. Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration. Surv Ophthalmol. 2014;59(1):1\u201318. https:\/\/doi.org\/10.1016\/j.survophthal.2013.03.009.","journal-title":"Surv Ophthalmol"},{"key":"4905_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/4367631","volume":"2016","author":"MK Tsilimbaris","year":"2016","unstructured":"Tsilimbaris MK, Lopez-Galvez MI, Gallego-Pinazo R, Margaron P, Lambrou GN. Epidemiological and clinical baseline characteristics as predictive biomarkers of response to anti-VEGF treatment in patients with neovascular AMD. J Ophthalmol. 2016;2016:1\u201313. https:\/\/doi.org\/10.1155\/2016\/4367631.","journal-title":"J Ophthalmol"},{"issue":"10","key":"4905_CR5","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/j.ophtha.2016.07.007","volume":"123","author":"D Sarraf","year":"2016","unstructured":"Sarraf D, London NJS, Khurana RN, Dugel PU, Gune S, Hill L, et al. Ranibizumab treatment for pigment epithelial detachment secondary to neovascular age-related macular degeneration: post hoc analysis of the HARBOR study. Ophthalmology. 2016;123(10):2213\u201324. https:\/\/doi.org\/10.1016\/j.ophtha.2016.07.007.","journal-title":"Ophthalmology"},{"issue":"4","key":"4905_CR6","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/IAE.0000000000002454","volume":"40","author":"A Mouallem-Beziere","year":"2020","unstructured":"Mouallem-Beziere A, Blanco-Garavito R, Richard F, Miere A, Jung C, Rozet J-M, et al. Genetics of large pigment epithelial detachments in neovascular age-related macular degeneration. Retina. 2020;40(4):663\u201371. https:\/\/doi.org\/10.1097\/IAE.0000000000002454.","journal-title":"Retina"},{"issue":"1","key":"4905_CR7","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1038\/s41598-022-06968-0","volume":"12","author":"GM Cozzupoli","year":"2022","unstructured":"Cozzupoli GM, Borrelli E, Capuano V, Sacconi R, Astroz P, Battista M, et al. InCASEOf scoring system for distinction between pachychoroid-associated macular neovascularization and neovascular age-related macular degeneration in patients older than 50 years. Sci Rep. 2022;12(1):2938. https:\/\/doi.org\/10.1038\/s41598-022-06968-0.","journal-title":"Sci Rep"},{"issue":"3","key":"4905_CR8","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/IAE.0b013e3182695ba0","volume":"33","author":"JA Montero","year":"2013","unstructured":"Montero JA, Ruiz-Moreno JM, Sanchis-Merino E, Perez-Martin S, et al. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab. Retina. 2013;33(3):508\u201312. https:\/\/doi.org\/10.1097\/IAE.0b013e3182695ba0.","journal-title":"Retina"},{"key":"4905_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2010\/546826","volume":"2010","author":"C Campa","year":"2010","unstructured":"Campa C, Costagliola C, Incorvaia C, Sheridan C, Semeraro F, De Nadai K, et al. Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications. Mediators Inflammation. 2010;2010:1\u201314. https:\/\/doi.org\/10.1155\/2010\/546826.","journal-title":"Mediators Inflammation"},{"issue":"3","key":"4905_CR10","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1001\/jamaophthalmol.2013.1476","volume":"131","author":"JA Lavine","year":"2013","unstructured":"Lavine JA, Sang Y, Wang S, Ip MS, Sheibani N, et al. Attenuation of choroidal neovascularization by \u03b22-adrenoreceptor antagonism. JAMA Ophthalmol. 2013;131(3):376\u201382. https:\/\/doi.org\/10.1001\/jamaophthalmol.2013.1476.","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"4905_CR11","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1007\/s00417-020-05048-1","volume":"259","author":"JG Garweg","year":"2021","unstructured":"Garweg JG, Gerhardt C. Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) \u2014 a meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2021;259(8):2181\u201392. https:\/\/doi.org\/10.1007\/s00417-020-05048-1.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"4905_CR12","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41433-022-02220-1","volume":"37","author":"DJ Fu","year":"2023","unstructured":"Fu DJ, Hanumunthadu D, Keenan TDL, Wagner S, Balsakas K, Keane PA, et al. Characterising treatment outcomes of patients achieving quarterly aflibercept dosing for neovascular age-related macular degeneration: real-world clinical outcomes from a large tertiary care centre. Eye. 2023;37(4):779\u201384. https:\/\/doi.org\/10.1038\/s41433-022-02220-1.","journal-title":"Eye"},{"issue":"4","key":"4905_CR13","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ophtha.2014.11.017","volume":"122","author":"U Schmidt-Erfurth","year":"2015","unstructured":"Schmidt-Erfurth U, Waldstein SM, Deak GG, Kundi M, Simader C, et al. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology. 2015;122(4):822\u201332. https:\/\/doi.org\/10.1016\/j.ophtha.2014.11.017.","journal-title":"Ophthalmology"},{"key":"4905_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.07.007","volume":"50","author":"U Schmidt-Erfurth","year":"2016","unstructured":"Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res. 2016;50:1\u201324. https:\/\/doi.org\/10.1016\/j.preteyeres.2015.07.007.","journal-title":"Prog Retin Eye Res"},{"issue":"12","key":"4905_CR15","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1136\/bjophthalmol-2014-305186","volume":"98","author":"M Ritter","year":"2014","unstructured":"Ritter M, Simader C, Bolz M, Deak GG, Mayr-Sponer U, Sayegh R, et al. Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy. Br J Ophthalmol. 2014;98(12):1629\u201335. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305186.","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"4905_CR16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/APO.0000000000000445","volume":"10","author":"V Chaikitmongkol","year":"2021","unstructured":"Chaikitmongkol V, Sagong M, Lai TYY, Tan GSW, Ngah NF, Ohji M, et al. Treat-and-extend regimens for the management of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: consensus and recommendations from the Asia-pacific vitreo-retina society. Asia-Pac J Ophthalmol. 2021;10(6):507\u201318. https:\/\/doi.org\/10.1097\/APO.0000000000000445.","journal-title":"Asia-Pac J Ophthalmol"},{"issue":"5","key":"4905_CR17","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","volume":"120","author":"BG Busbee","year":"2013","unstructured":"Busbee BG, Ho AC, Brown DM, Heier JS, Su\u00f1er IJ, Li Z, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046\u201356. https:\/\/doi.org\/10.1016\/j.ophtha.2012.10.014.","journal-title":"Ophthalmology"},{"issue":"11","key":"4905_CR18","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","volume":"121","author":"AC Ho","year":"2014","unstructured":"Ho AC, Busbee BG, Regillo CD, Wieland MR, Van Everen SA, Li Z, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121(11):2181\u201392. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.009.","journal-title":"Ophthalmology"},{"key":"4905_CR19","doi-asserted-by":"publisher","unstructured":"Shona O, Gupta B, Vemala R, Sivaprasad SJ, et al. Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision. Clin Exp Ophthalmol. 2011;39:no-no. https:\/\/doi.org\/10.1111\/j.1442-9071.2010.02424.x.","DOI":"10.1111\/j.1442-9071.2010.02424.x"},{"issue":"7","key":"4905_CR20","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.ophtha.2016.03.037","volume":"123","author":"SM Waldstein","year":"2016","unstructured":"Waldstein SM, Simader C, Staurenghi G, Chong NV, Mitchell P, Jaffe GJ, et al. Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials. Ophthalmology. 2016;123(7):1521\u201329. https:\/\/doi.org\/10.1016\/j.ophtha.2016.03.037.","journal-title":"Ophthalmology"},{"issue":"1","key":"4905_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ophtha.2015.09.013","volume":"123","author":"SM Waldstein","year":"2016","unstructured":"Waldstein SM, Wright J, Warburton J, Margaron P, Simader C, Schmidt-Erfurth U. Predictive value of retinal morphology for visual acuity outcomes of different ranibizumab treatment regimens for neovascular AMD. Ophthalmology. 2016;123(1):60\u201369. https:\/\/doi.org\/10.1016\/j.ophtha.2015.09.013.","journal-title":"Ophthalmology"},{"issue":"24","key":"4905_CR22","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1056\/NEJMc0708819","volume":"358","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Ta\u00efeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649\u201351. https:\/\/doi.org\/10.1056\/NEJMc0708819.","journal-title":"N Engl J Med"},{"issue":"12","key":"4905_CR23","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/ddg.13365","volume":"15","author":"A Rotter","year":"2017","unstructured":"Rotter A, Prado de Oliveira ZNP. Infantile hemangioma: pathogenesis and mechanisms of action of propranolol. J Deutsche Derma Gesell. 2017;15(12):1185\u201390. https:\/\/doi.org\/10.1111\/ddg.13365.","journal-title":"J Deutsche Derma Gesell"},{"issue":"1","key":"4905_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","volume":"148","author":"GA Lalwani","year":"2009","unstructured":"Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer WJ, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol. 2009;148(1):43\u201358.e1. https:\/\/doi.org\/10.1016\/j.ajo.2009.01.024.","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"4905_CR25","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","volume":"36","author":"LN Kim","year":"2016","unstructured":"Kim LN, Mehta H, Barthelmes D, Nguyen V, Gillies MC, et al. Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration. Retina. 2016;36(8):1418\u201331. https:\/\/doi.org\/10.1097\/IAE.0000000000001142.","journal-title":"Retina"},{"issue":"3","key":"4905_CR26","doi-asserted-by":"publisher","first-page":"331","DOI":"10.18502\/jovr.v15i3.7452","volume":"15","author":"A Lee","year":"2020","unstructured":"Lee A, Garg PG, Lyon AT, Mirza R, K Gill M, et al. Long-term outcomes of treat and extend regimen of anti-vascular endothelial growth factor in neovascular age-related macular degeneration. JOVR. 2020;15(3):331\u201340. https:\/\/doi.org\/10.18502\/jovr.v15i3.7452.","journal-title":"JOVR"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-04905-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04905-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04905-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:15:32Z","timestamp":1783984532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-04905-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4905"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-04905-7","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted at the ophthalmology clinic of a tertiary healthcare institution and ethical approval was obtained for the study from Ankara Bilkent City Hospital Ethics Committee (E1\/3295\/2023). The research was carried out in accordance with the principles of the Declaration of Helsinki. Since the study was retrospective, the ethics committee did not deem it necessary to obtain patient consent. The requirement for informed consent was waived because of the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"409"}}